Abstract
The collected Chapters in this volume describe the current status of poly(ethylene glycol) (PEG) modification of proteins, peptides, oligonucleotides and small molecule drugs, the recent advances in conjugation chemistry, and new clinical products. The book provides an excellent update in this rapidly evolving field, and the comprehensive collection of Chapters complements well past reviews/volumes that have documented the evolution of PEGylation. For example, a reader new to this field is encouraged to gain the historical perspective by reading the following reviews [1–8]. Only then is it possible to see just how far this field has come and understand that it has already established a new class of therapeutics as we start the 21st Century!
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
- Conjugation Chemistry
- Macromolecular Drug
- High Molecular Weight PEGs
- Macromolecular Prodrug
- Polymer Therapeutics
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Fuertges F, Abuchowski A (1990) The clinical efficacy of poly(ethyleneglycol)-modified proteins. J Controlled Rel 11: 139–148
Nucci ML, Shorr R, Abuchowski A (1991) The therapeutic values of poly(ethylene glycol)-mod-ified proteins. Adv Drug Delivery Rev 6: 133–151
Francis GE, Delgado C, Fisher D, Malik F, Argrawl AK (1996) Polyethylene glycol modification: Relevance to improved methodology to tumour targeting. J Drug Targeting 3: 321–340
Davis FF (2002) The origin of pegnology. Adv Drug Del Rev 54: 457–458
Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nature Rev Drug Discov 2: 214–221
Veronese FM, Harris JM (Eds) (2002) Introduction and overview of peptide and protein pegylation. Adv Drug Deliv Rev 54: 453–609
Harris JM, Veronese FM (Eds) Pegylation of peptides and proteins II — Clinical Evaluation. Adv Drug Deliv Rev 55: 1261–1277
Veronese FM, Harris JM (Eds) (2008) Pegylation of peptides and proteins III: Advances in chemistry and clinical applications. Adv Drug Deliv Rev 60: 1–87
Duncan R (2005) Targeting and intracellular delivery of drugs. In: RA Meyers (ed.): Encyclopedia of Molecular Cell Biology and Molecular Medicine. Wiley-VCH Verlag, GmbH & Co. KGaA, Weinheim, Germany, 163–204
Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nature Rev Drug Discov 2: 750–763
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discov 4: 145–160
Couvreur P, Vauthier C (2006) Nanotechnology: Intelligent design to treat complex disease. Pharm Res 23:1417–1450
Duncan R (2003) The dawning era of polymer therapeutics. Nat Rev Drug Discov 2: 347–360
Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6: 688–701
US Food and Drug Administration accessed at http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/
Ferrari M (2005) Cancer nanotechnology: Opportunities and challenges. Nature Rev Cancer 5: 161–171
European Science Foundation Forward Look on Nanomedicine (2005) http://www.esf.org
Ringsdorf H (2004) Hermann Staudingerand the Future of Polymer Research: Jubilees — Beloved Occasions for Cultural Piety. Angew Chem Int Ed 43: 1064–1076
Gros L, Ringsdorf H, Schupp H (1981) Polymerie antitumour agents on a molecular and cellular level. Angew Chemie Int Ed Eng 20: 301–323
Regelson W, Parker G (1986) The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy. Cancer Invest 4: 29–42
Ringsdorf H (1975) Structure and properties of pharmacologically active polymers. J Polymer Sci Polymer Symp 51:135–153
Lee CC, MacKay JA, Fréchet JMJ, Szoka FC (2005) Designing dendrimers for biological applications. Nature Biotechnol 23: 1517–1526
Ng EWM, Shima DT, Calias P, Cunningham Jr ET, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Rev Drug Discov 5:125–132
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, Deventer SV, Goldblum R, Despain D, Hogge GS, Rutgeerts P (2005) Natalizumab induction and maintenance therapy for Crohn’s disease N Engl J Med 353(18): 1912–1935
Eldar-Lissai A, Cosier LE, Culakova E, Lyman GH (2008) Economic analysis of prophylactic peg-filgrastim in adult cancer patients receiving chemotherapy. Value Health 11: 172–179
Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y (2007) A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. Acta Gastroenterol Belg 70: 177–187
Eaton M (2007) Nanomedicine: industry-wise research, Nature Mater 6: 251–253
Gaspar R (2007) Regulatory issues surrounding nanomedicines: setting the scene for the nextgeneration of nanopharmaceuticals. Nanomedicine 2: 143–147
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
Duncan, R., Veronese, F.M. (2009). Preface PEGylated protein conjugates: A new class of therapeutics for the 21st century. In: Veronese, F.M. (eds) PEGylated Protein Drugs: Basic Science and Clinical Applications. Milestones in Drug Therapy. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8679-5_1
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8678-8
Online ISBN: 978-3-7643-8679-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)